UNSPSC 51281513: Ethambutol hydrochloride

This classification denotes an antitubercular agent with the molecular formula C10H24N2O2.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QE4VW5FO07, chemically known as 2,2-(1,2-ethylenediimino)-di-1-butanol but more generally known as ethambutol hydrochloride, which bears US NIH Compound Identifier 3279. European Medicines Agency schedules Ethambutol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11945MIG.

Most nations, for tariff and trade purposes, schedule ethambutol hydrochloride under HS 29221980. As of Q4 2014, ETHAMBUTOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Ethambutol hydrochloride bears US NLM identifiers UMLS ID C0026895 and NCI Concept Code C29033. SMILES: CC[C@@H](CO)NCCN[C@@H](CC)CO.CL.CL.

UNSPSC 51281513 Ethambutol hydrochloride is a Commodity code that in practice captures a narrow slice of pharmaceutical procurement — but the recent opportunities tagged to it show little alignment with the code's nominal scope. The four most recent state and local solicitations under this code involve naloxone and drug deactivation systems (Seminole County, Florida), a therapeutic pharmacy initiative RFI for direct-to-manufacturer prescription programs (Texas Health and Human Services Commission), medical and first aid supplies for emergency response (City of Tampa Fire Department), and generic multi-source pharmaceuticals and OTC products through cooperative purchasing (Minnesota Multistate Cooperative Purchasing Alliance). None of these procurement streams center on ethambutol hydrochloride itself. The breadth of products being solicited — from emergency naloxone to broad generic drug catalogs — suggests that state and local procurement systems are applying this Commodity code to pharmaceutical acquisitions more broadly rather than to a specific active pharmaceutical ingredient.

Activity appears concentrated among health departments, emergency services departments, and state pharmacy benefit programs across Florida, Texas, and Minnesota, with cooperative purchasing vehicles playing a notable role. The most recent opportunity is Seminole County's IFB for 1,900 units of naloxone and 800 drug deactivation systems annually (due July 26, 2023), which requires quarterly deliveries and includes FEMA compliance. The City of Tampa issued an IFB for 169 line items of medical and first aid supplies for the Fire Department Rescue Division with an estimated contract value of $700,000 (due March 13, 2026), designated as a sheltered market for certified Small Local Business Enterprises with a 5 percent bid discount. The Minnesota Multistate Cooperative Purchasing Alliance released an RFP for generic multi-source pharmaceuticals and OTC products due March 26, 2026, requiring vendors to work through three authorized wholesalers and accept a 3 percent administrative fee. The Texas Health and Human Services Commission posted an RFI on March 27, 2026 (due April 3, 2026) to explore direct-to-manufacturer prescription programs outside traditional PBM and GPO channels. The code shows active procurement but with significant mismatch between its nominal scope and the work actually being solicited.